Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | BGB-11417 |
Trade Name | |
Synonyms | BGB 11417|BGB11417|Sonrotoclax |
Drug Descriptions |
BGB-11417 selectively inhibits Bcl2, which potentially leads to decreased tumor cell proliferation and inhibition of tumor growth (Cancer Res 2020;80(16 Suppl):Abstract nr 3077). |
DrugClasses | BCL2 inhibitor 27 |
CAS Registry Number | NA |
NCIT ID | C175489 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Azacitidine + BGB-11417 | Azacitidine BGB-11417 | 0 | 1 |
Azacitidine + BGB-11417 + Posaconazole | Azacitidine BGB-11417 Posaconazole | 0 | 0 |
BGB-11417 | BGB-11417 | 0 | 3 |
BGB-11417 + Carfilzomib + Dexamethasone | BGB-11417 Carfilzomib Dexamethasone | 0 | 1 |
BGB-11417 + Dexamethasone | BGB-11417 Dexamethasone | 0 | 1 |
BGB-11417 + Zanubrutinib | BGB-11417 Zanubrutinib | 0 | 3 |